Recent News

• 04.24.2025 - Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting
• 04.22.2025 - Genprex Announces Research Collaborators’ Abstract Published in Cancer Research Supplement Proceedings
• 03.26.2025 - Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting
• 03.25.2025 - Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
• 03.04.2025 - Genprex to Participate at BIO Europe Spring 2025
• 02.19.2025 - Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System
• 02.18.2025 - Genprex Provides Update on Diabetes Gene Therapy Program
• 02.13.2025 - Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer
• 01.23.2025 - Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Recent Filings

• 04.01.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.01.2025 - NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
• 02.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.18.2025 - EX-99.1 EX-99.1
• 02.18.2025 - 8-K Current report
• 02.12.2025 - 8-K Current report
• 01.24.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 01.23.2025 - 8-K Current report
• 01.15.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors